Compare Synopsys, Inc. (SNPS) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs 22nd Century Group Inc — how do they compare? Synopsys, Inc. trades at $413 (market cap $78.68B), while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: Synopsys, Inc. is far larger — about 51763.2× 22nd Century Group Inc's market cap, and Synopsys, Inc. is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| SNPS | XXII | |
|---|---|---|
Market Cap | $78.68B | $1.52M |
Sector | Technology | Technology |
52-Week High | $625.80 | $801.00 |
52-Week Low | $372.33 | $3.72 |
Enterprise Value | $87.04B | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $412.06, up 0.09% on the day, with a bearish technical signal despite recent earnings beats. The stock shows high valuation ratios (P/E 94.03, P/S 8.68) and a net income margin of 8.91%. Recent news highlights AI-driven growth potential from the Ansys acquisition and agentic EDA workflows, though cash flow trends show volatility with a net outflow of $1.01B in 2025.
Outlook remains positive with analyst consensus favoring Buy (82.76%) and a $551 price target, but risks include elevated valuation, competitive pressures, and integration challenges from acquisitions. The stock offers growth exposure to semiconductor design software but requires monitoring of execution and market sentiment shifts.
22nd Century Group (XXII) trades at $4.31, down 0.92% on the day, with a neutral technical signal and bearish moving averages. The company shows deep unprofitability with a gross margin of -52.19% and net margin of -65.76%, though revenue was $7.05M in 2025. Recent corporate actions include a 20:1 reverse stock split in June 2026, and news highlights retail expansion for VLN reduced-nicotine cigarettes in California and New York.
The outlook remains speculative with high execution risk amid persistent losses, but analyst sentiment is bullish with 75% buy ratings. Key risks include negative cash flow from operations, regulatory hurdles for tobacco products, and the need for successful commercialization of VLN to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
